PAVmed (NASDAQ: PAVM) posted Q4 2025 GAAP net loss of approximately $1.8 million (diluted EPS of -$2.05, non-GAAP EPS of -$1.05), beating the analyst consensus estimate of -$4.62 by 77.27%. Full-year revenue came in at $71,000, a steep decline driven primarily by the September 2024 deconsolidation of subsidiary Lucid Diagnostics. Pre-market stock saw an after-hours movement of +3.81% on earnings day, reflecting investor optimism over the completed balance sheet recapitalization.
About PAVmed Inc.
PAVmed Inc. (NASDAQ: PAVM) is a diversified commercial-stage medical technology company headquartered in New York City, operating in the medical device, diagnostics, and digital health sectors. Founded in 2014, the company operates through a multi-subsidiary model that includes Lucid Diagnostics Inc. (NASDAQ: LUCD), a commercial-stage cancer prevention diagnostics company, and Veris Health Inc., a digital health platform focused on personalized cancer care through remote patient monitoring using implantable biologic sensors.
PAVmed’s flagship diagnostic offering through Lucid is the EsoGuard Esophageal DNA Test, used for early detection of esophageal precancer among patients with chronic acid reflux. As of the earnings release date, the company had a market capitalization of approximately $57.5 million, with 6.32 million shares outstanding (post-reverse-split), no dividend yield, and an employee count of approximately 39. The company carries a current ratio of 0.17x, reflecting significant short-term liquidity constraints.
Top Financial Highlights
- Q4 2025 revenue was $52,000 vs. $10,000 in Q4 2024, a 420% increase – though revenue at these micro-levels is largely symbolic
- Full-year 2025 revenue reached $71,000, down -97.63% from $2.995 million in full-year 2024, primarily due to the deconsolidation of Lucid Diagnostics in September 2024
- Q4 2025 GAAP net loss attributable to common stockholders was $1.832 million, or $(2.05) per diluted share
- Q4 2025 non-GAAP adjusted loss was approximately $942,000, or $(1.05) per diluted share
- Full-year 2025 GAAP net loss before non-controlling interest and preferred dividends was approximately $2.469 million (loss from operations was $21.877 million in operating expenses)
- Full-year 2025 loss per diluted share stood at $(5.63), versus full-year 2024 diluted EPS of $14.90
- Q4 2025 total operating expenses were approximately $6.9 million, including $0.3 million in stock-based compensation
- Full-year 2025 operating expenses totaled $21.877 million, a significant reduction from $47.482 million in 2024
- Cash and cash equivalents as of December 31, 2025 were $1.5 million, up from $1.2 million at year-end 2024
- Q4 2025 cash burn rate was approximately $1.5 million per quarter
- PAVmed completed a $30 million Series D preferred stock offering and a $15 million senior secured note financing in early 2026, bringing pro forma total assets to over $100 million
- The company issued $30 million in Series D warrants, callable upon the publication of a draft CMS coverage policy for Lucid’s EsoGuard test
- Lucid Diagnostics (subsidiary) recognized $1.5 million in EsoGuard revenue for Q4 2025 and processed 3,664 EsoGuard tests, a 29% increase in volume and 24% increase in revenue versus Q3 2025
- PAVmed equity method investment (Lucid shares mark-to-market) stood at $34 million at year-end, reflecting a 33% increase in Lucid stock during 2025
- One analyst rating: Strong Buy, price target $510.00
Beat or Miss?
| Metric | Reported | Estimated | Difference / Analysis |
| Q4 2025 Non-GAAP EPS | ($1.05) | ($4.62) | Beat by $3.57 (77.27%) |
| Q4 2025 GAAP EPS (diluted) | ($2.05) | N/A | No GAAP consensus available |
| Full-Year 2025 Revenue | $71,000 | N/A | -97.63% YoY; no formal consensus estimate |
| Full-Year 2025 Net Loss (before NCI) | -$2.469M | N/A | Materially lower than 2024 net income of $39.79M (driven by one-time 2024 Lucid deconsolidation gain) |
| Cash on Hand (Dec 31, 2025) | $1.5M | N/A | Slight improvement from $1.2M at prior year-end |
| Q4 2025 Operating Expenses | $6.9M | N/A | Includes $0.3M SBC; net non-GAAP OpEx ~$6.25M |
| Q4 2025 Lucid EsoGuard Revenue | $1.5M | N/A | +24% vs Q3 2025 ($1.2M) |
What Leadership Is Saying?
CEO – Strategy and Vision
“Over the past two years, we’ve undertaken a series of deliberate, systematic actions to fix PAVmed’s legacy capital structure and strengthen its balance sheet. This process is now complete and we believe PAVmed is exceptionally well positioned to execute on its founding mission – to operate as a high-growth diversified commercial life sciences company with multiple independently financed subsidiaries operating under a shared services model. Veris is now well underway in the commercial phase of its strategic engagement with OSU-The James while progressing its implantable physiological monitor toward FDA submission. Lucid continues to maintain a strong commercial foundation as it approaches transformative Medicare coverage for EsoGuard.” – Lishan Aklog, M.D., Chairman and Chief Executive Officer, PAVmed Inc.
CFO – Financials and Capital Structure
“With regard to the balance sheet, the company is engaged in a multi-step process to regain compliance with the Nasdaq listing standard for minimum equity… This was a multi-step process that spanned nearly 18 months with 3 key recapitalization steps landing PAVmed on firm financial footing with its recent financing that closed on February 3. After the financing in February, the far right column now illustrates a company with total assets over $100 million and $15 million of long-term debt.” – Dennis McGrath, President and Chief Financial Officer, PAVmed Inc.
Historical Performance
| Category | Q4 2025 | Q4 2024 | Change (%) |
| Revenue | $52,000 | $10,000 | 420% |
| GAAP Net Income (Loss) to Common Stockholders | -$1.832M | +$1.346M | N/M (swing to loss) |
| Total Operating Expenses | $6.853M | $5.198M | 31.80% |
| Non-GAAP Adjusted Loss | -$942K | -$688K | 36.90% |
| Non-GAAP EPS | ($1.05) | ($1.91) | +45.0% improvement |
| Cash and Equivalents | $1.5M | $1.2M | 25.00% |
Full-Year Comparison (2025 vs 2024)
| Category | FY 2025 | FY 2024 | Change (%) |
| Revenue | $71,000 | $2.995M | -97.63% |
| Net Income (Loss) Before NCI | -$2.469M | +$28.427M | N/M (reversal – 2024 included one-time Lucid deconsolidation gain of $72.3M) |
| Total Operating Expenses | $21.877M | $47.482M | -53.90% |
| GAAP Diluted EPS | ($5.63) | $14.90 | N/M |
| Non-GAAP Adjusted Loss | -$3.141M | -$22.41M | +86.0% improvement |
Competitor Comparison
The table below compares PAVmed and key competitors in the cancer diagnostics and medical technology space. Note that PAVmed’s revenue reflects post-Lucid-deconsolidation operations, making direct comparisons complex.
| Company | FY 2025 Revenue (approx.) | FY 2024 Revenue (approx.) | YoY Change | Notes |
| PAVmed Inc. (PAVM) | $71K | $2.995Mp | -97.60% | Revenue collapse due to Lucid deconsolidation (Sept 2024); subsidiary Lucid separately listed on NASDAQ |
| Lucid Diagnostics (LUCD) | ~$5M (est. FY2025) | ~$3M | ~+67% | EsoGuard; Q4 2025 revenue $1.5M (+24% QoQ); VA contract win in 2026; Medicare coverage pending |
| Exact Sciences (EXAS) | Multi-billion (Cologuard flagship) | N/A cited | High growth | Commercial-stage oncology diagnostics leader; flagship Cologuard test |
| Guardant Health (GH) | High-revenue liquid biopsy leader | N/A cited | Expansion phase | Liquid biopsy precision oncology; broader cancer applications than EsoGuard |
How the Market Reacted?
PAVmed shares gained 3.81% in pre-market trading on March 30, 2026, immediately following the Q4 2025 earnings release, reflecting positive investor sentiment around the completed balance sheet recapitalization and the elimination of toxic convertible securities. This pre-market uptick contrasted with a challenging prior week during which shares had declined 11.8%, and the stock remained down approximately 61.47% over the prior 12 months.
The year-to-date gain through the earnings date stood at 30.89%, largely driven by the announced Series D financing and capital structure cleanup. Given the deeply discounted stock – which had traded near its 52-week low of $6.00 and remained far below its historical peak – market sentiment heading into the earnings call reflected deep skepticism, with investors focused specifically on Lucid Diagnostics’ EsoGuard test volume trajectory and Veris Health’s FDA submission timeline as the two primary execution metrics for the year ahead.
